{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:25Z","timestamp":1790713045069,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473334"],"award-info":[{"award-number":["82473334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471551"],"award-info":[{"award-number":["32471551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Scientific and Technological Achievements Transformation Project of Ningxia Hui Autonomous Region","award":["2022CJE09013"],"award-info":[{"award-number":["2022CJE09013"]}]},{"name":"Project Fund of Sichuan Provincial Healthommission","award":["24CXTD15"],"award-info":[{"award-number":["24CXTD15"]}]},{"name":"Mianyang Science and Technology Bureau","award":["2023ZYDF097"],"award-info":[{"award-number":["2023ZYDF097"]}]},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformatio","award":["NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL)"],"award-info":[{"award-number":["NHC Key Laboratory of Nuclear Technology Medical Transformation(MIANYANG CENTRAL HOSPITAL)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07321-5","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:15:02Z","timestamp":1764864902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel immunocytokine promotes T cell\u2013 and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiaoke","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingbin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-6358","authenticated-orcid":false,"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"7321_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","volume":"6","author":"E Dahl\u00e9n","year":"2018","unstructured":"Dahl\u00e9n E, Veitonm\u00e4ki N, Norl\u00e9n P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6:3\u201317.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"7321_CR2","doi-asserted-by":"crossref","unstructured":"Lim K, Zhu X (Sue), Zhou D, Ren S, Phipps A, editors. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116:315\u201327.","DOI":"10.1002\/cpt.3308"},{"key":"7321_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting Immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023;20:181\u201395.","journal-title":"Cancer Biol Med"},{"key":"7321_CR4","unstructured":"Research C, for DE and Bispecific antibodies: an area of research and clinical applications. FDA [Internet] 2024 [cited 2025 Mar 8];Available from: https:\/\/www.fda.gov\/drugs\/spotlight-cder-science\/bispecific-antibodies-area-research-and-clinical-applications"},{"key":"7321_CR5","unstructured":"CBTRUS Statistical Report. Primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020 - PubMed [Internet]. [cited 2024 Aug 29]; Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37793125\/"},{"key":"7321_CR6","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.smim.2020.101385","volume":"47","author":"T Nejo","year":"2020","unstructured":"Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H. Tumor antigens in glioma. Semin Immunol. 2020;47:101385.","journal-title":"Semin Immunol"},{"key":"7321_CR7","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396\u2013401.","journal-title":"Science"},{"key":"7321_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20:12\u201325.","journal-title":"Nat Rev Cancer"},{"key":"7321_CR9","first-page":"256","volume":"6","author":"V Dutoit","year":"2016","unstructured":"Dutoit V, Migliorini D, Dietrich PY, Walker PR. Immunotherapy of malignant tumors in the brain: how different from other sites? Front. Oncol. 2016;6:256.","journal-title":"Oncol"},{"key":"7321_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014\u201322.","journal-title":"Nat Immunol"},{"key":"7321_CR11","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","volume":"28","author":"E Lanitis","year":"2017","unstructured":"Lanitis E, Dangaj D, Irving M, Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:xii18\u201332.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"7321_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.ccr.2007.04.017","volume":"11","author":"S Seaman","year":"2007","unstructured":"Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C. St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. 2007;11:539\u201354.","journal-title":"Cancer Cell"},{"key":"7321_CR13","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.7150\/ijbs.85813","volume":"19","author":"X Guo","year":"2023","unstructured":"Guo X, Chang M, Wang Y, Xing B, Ma W. B7-H3 in brain malignancies: immunology and immunotherapy. Int J Biol Sci. 2023;19:3762\u201380.","journal-title":"Int J Biol Sci"},{"key":"7321_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","volume":"23","author":"D Haydar","year":"2021","unstructured":"Haydar D, Houke H, Chiang J, Yi Z, Od\u00e9 Z, Caldwell K, et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro-Oncol. 2021;23:999\u20131011.","journal-title":"Neuro-Oncol"},{"key":"7321_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic Pontine glioma: preliminary First-in-Human bioactivity and safety. Cancer Discov. 2023;13:114\u201331.","journal-title":"Cancer Discov"},{"key":"7321_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s10637-018-00719-7","volume":"37","author":"J Ma","year":"2019","unstructured":"Ma J, Shang T, Ma P, Sun X, Zhao J, Sun X, et al. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. Invest New Drugs. 2019;37:1036\u201343.","journal-title":"Invest New Drugs"},{"key":"7321_CR17","doi-asserted-by":"publisher","first-page":"9126","DOI":"10.1021\/acsnano.2c12217","volume":"17","author":"R Fan","year":"2023","unstructured":"Fan R, Chen C, Mu M, Chuan D, Liu H, Hou H, et al. Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for Ferroptosis-Enhanced glioblastoma immunotherapy. ACS Nano. 2023;17:9126\u201339.","journal-title":"ACS Nano"},{"key":"7321_CR18","doi-asserted-by":"publisher","first-page":"12185","DOI":"10.1021\/acsnano.2c02850","volume":"16","author":"EA Mews","year":"2022","unstructured":"Mews EA, Beckmann P, Patchava M, Wang Y, Largaespada DA, Wagner CR, Multivalent. Bispecific \u03b1B7-H3-\u03b1CD3 chemically Self-Assembled nanorings direct potent T cell responses against Medulloblastoma. ACS Nano. 2022;16:12185\u2013201.","journal-title":"ACS Nano"},{"key":"7321_CR19","doi-asserted-by":"publisher","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","volume":"10","author":"C Aggarwal","year":"2022","unstructured":"Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, et al. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial. J Immunother Cancer. 2022;10:e004424.","journal-title":"J Immunother Cancer"},{"key":"7321_CR20","doi-asserted-by":"crossref","unstructured":"DeSantes KB, McDowell KA, Sondel PM, Hutson PR, Kaplan RN, Park JR, et al. A phase I, open-label, dose escalation study of enoblituzumab in children and young adults with B7-H3-expressing relapsed or refractory solid tumors. Cancer Res Commun. 2025.","DOI":"10.1158\/2767-9764.c.8026629"},{"key":"7321_CR21","doi-asserted-by":"publisher","first-page":"O8","DOI":"10.1186\/2051-1426-3-S2-O8","volume":"3","author":"J Powderly","year":"2015","unstructured":"Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, et al. Interim results of an ongoing phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer. 2015;3:O8.","journal-title":"J Immunother Cancer"},{"key":"7321_CR22","doi-asserted-by":"publisher","unstructured":"Tolcher AW, Alley EW, Chichili G, Baughman JE, Moore PA, Bonvini E, et al. Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature. J. Clin. Oncol. [Internet]. 2016 [cited 2025 Aug 13];Available from: https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.TPS3105","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS3105"},{"key":"7321_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/cancers13020287","volume":"13","author":"J Middelburg","year":"2021","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-Bispecific antibody therapy in solid tumors. Cancers. 2021;13:287.","journal-title":"Cancers"},{"key":"7321_CR24","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-15-3451","volume":"76","author":"M Hettich","year":"2016","unstructured":"Hettich M, Lahoti J, Prasad S, Niedermann G. Checkpoint antibodies but not T Cell-Recruiting diabodies effectively synergize with TIL-Inducing \u03b3-Irradiation. Cancer Res. 2016;76:4673\u201383.","journal-title":"Cancer Res"},{"key":"7321_CR25","doi-asserted-by":"publisher","first-page":"eabb2311","DOI":"10.1126\/scitranslmed.abb2311","volume":"12","author":"T Weiss","year":"2020","unstructured":"Weiss T, Puca E, Silginer M, Hemmerle T, Pazahr S, Bink A, et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci Transl Med. 2020;12:eabb2311.","journal-title":"Sci Transl Med"},{"key":"7321_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/sj.bjc.6605832","volume":"103","author":"M Pedretti","year":"2010","unstructured":"Pedretti M, Verpelli C, M\u00e5rlind J, Bertani G, Sala C, Neri D, et al. Combination of Temozolomide with Immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer. 2010;103:827\u201336.","journal-title":"Br J Cancer"},{"key":"7321_CR27","doi-asserted-by":"publisher","first-page":"e008880","DOI":"10.1136\/jitc-2024-008880","volume":"12","author":"PK Bommareddy","year":"2024","unstructured":"Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. J Immunother Cancer. 2024;12:e008880.","journal-title":"J Immunother Cancer"},{"key":"7321_CR28","doi-asserted-by":"publisher","first-page":"1117092","DOI":"10.3389\/fimmu.2023.1117092","volume":"14","author":"J Lee","year":"2023","unstructured":"Lee J, Lee K, Bae H, Lee K, Lee S, Ma J, et al. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation. Front Immunol. 2023;14:1117092.","journal-title":"Front Immunol"},{"key":"7321_CR29","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.4110\/in.2024.24.e11","volume":"24","author":"H Lee","year":"2024","unstructured":"Lee H, Park SH, Shin EC. IL-15 in T-Cell responses and Immunopathogenesis. Immune Netw. 2024;24:e11.","journal-title":"Immune Netw"},{"key":"7321_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7:759\u201372.","journal-title":"Cancer Immunol Res"},{"key":"7321_CR31","doi-asserted-by":"publisher","first-page":"216760","DOI":"10.1016\/j.canlet.2024.216760","volume":"588","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yang N, Lu H, Chen Y, Xu L, Wang Z, et al. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb\/CD3 BsAb. Cancer Lett. 2024;588:216760.","journal-title":"Cancer Lett"},{"key":"7321_CR32","doi-asserted-by":"crossref","unstructured":"Zhao S, Wang Y, Yang N, Mu M, Wu Z, Li H, et al. Genome-scale CRISPR\u2013Cas9 screen reveals novel regulators of B7-H3 in tumor cells. J. Immunother. Cancer [Internet] 2022 [cited 2025 Aug 13];10. Available from: https:\/\/jitc.bmj.com\/content\/10\/6\/e004875","DOI":"10.1136\/jitc-2022-004875"},{"key":"7321_CR33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-18-1522","volume":"9","author":"E Driehuis","year":"2019","unstructured":"Driehuis E, Kolders S, Spelier S, L\u00f5hmussaar K, Willems SM, Devriese LA, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discov. 2019;9:852\u201371.","journal-title":"Cancer Discov"},{"key":"7321_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41596-020-00467-0","volume":"16","author":"S Kiesgen","year":"2021","unstructured":"Kiesgen S, Messinger JC, Chintala NK, Tano Z, Adusumilli PS. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. Nat Protoc. 2021;16:1331\u201342.","journal-title":"Nat Protoc"},{"key":"7321_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","volume":"31","author":"G Wang","year":"2023","unstructured":"Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther J Am Soc Gene Ther. 2023;31:134\u201353.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"7321_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymgme.2018.05.003","volume":"124","author":"I Slavc","year":"2018","unstructured":"Slavc I, Cohen-Pfeffer JL, Gururangan S, Krauser J, Lim DA, Maldaun M, et al. Best practices for the use of intracerebroventricular drug delivery devices. Mol Genet Metab. 2018;124:184\u20138.","journal-title":"Mol Genet Metab"},{"key":"7321_CR37","doi-asserted-by":"publisher","first-page":"1893500","DOI":"10.1080\/2162402X.2021.1893500","volume":"10","author":"H Xu","year":"2021","unstructured":"Xu H, Buhtoiarov IN, Guo H, Cheung NKV. A novel multimeric IL15\/IL15R\u03b1-Fc complex to enhance cancer immunotherapy. Oncoimmunology. 2021;10:1893500.","journal-title":"Oncoimmunology"},{"key":"7321_CR38","doi-asserted-by":"publisher","first-page":"e008572","DOI":"10.1136\/jitc-2023-008572","volume":"12","author":"I S\u00e1nchez-Moreno","year":"2024","unstructured":"S\u00e1nchez-Moreno I, Lasarte-Cia A, Mart\u00edn-Otal C, Casares N, Navarro F, Gorraiz M, et al. Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model. J Immunother Cancer. 2024;12:e008572.","journal-title":"J Immunother Cancer"},{"key":"7321_CR39","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted bites complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther J Am Soc Gene Ther. 2022;30:2537\u201353.","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"7321_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting bites circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37:1049\u201358.","journal-title":"Nat Biotechnol"},{"key":"7321_CR41","doi-asserted-by":"publisher","first-page":"1983306","DOI":"10.1080\/2162402X.2021.1983306","volume":"10","author":"G Li","year":"2021","unstructured":"Li G, Zhang Z, Cai L, Tang X, Huang J, Yu L, et al. Fn14-targeted bite and CAR-T cells demonstrate potent preclinical activity against glioblastoma. Oncoimmunology. 2021;10:1983306.","journal-title":"Oncoimmunology"},{"key":"7321_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","volume":"38","author":"Y Guo","year":"2017","unstructured":"Guo Y, Luan L, Patil NK, Sherwood ER. Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017;38:10\u201321.","journal-title":"Cytokine Growth Factor Rev"},{"key":"7321_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-21-0058","volume":"9","author":"Y Xu","year":"2021","unstructured":"Xu Y, Carrascosa LC, Yeung YA, Chu MLH, Yang W, Djuretic I, et al. An engineered IL15 cytokine Mutein fused to an Anti-PD1 improves intratumoral T-cell function and antitumor immunity. Cancer Immunol Res. 2021;9:1141\u201357.","journal-title":"Cancer Immunol Res"},{"key":"7321_CR44","doi-asserted-by":"crossref","unstructured":"Maire CL, Mohme M, Bockmayr M, Fita KD, Riecken K, B\u00f6rnigen D, et al. Glioma escape signature and clonal development under immune pressure. J Clin Invest. 2020;130:5257\u201371.","DOI":"10.1172\/JCI138760"},{"key":"7321_CR45","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3390\/biology12121528","volume":"12","author":"C Yu","year":"2023","unstructured":"Yu C, Hsieh K, Cherry DR, Nehlsen AD, Resende Salgado L, Lazarev S, et al. Immune escape in glioblastoma: mechanisms of action and implications for immune checkpoint inhibitors and CAR T-Cell therapy. Biology. 2023;12:1528.","journal-title":"Biology"},{"key":"7321_CR46","doi-asserted-by":"publisher","first-page":"e003679","DOI":"10.1136\/jitc-2021-003679","volume":"9","author":"K Singh","year":"2021","unstructured":"Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer. 2021;9:e003679.","journal-title":"J Immunother Cancer"},{"key":"7321_CR47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","volume":"43","author":"H Li","year":"2025","unstructured":"Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, et al. Distinct CD8\u2009+\u2009T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025;43:757\u2013e7758.","journal-title":"Cancer Cell"},{"key":"7321_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E Landoni","year":"2024","unstructured":"Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, et al. IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat Commun. 2024;15:89.","journal-title":"Nat Commun"},{"key":"7321_CR49","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/neuonc\/nov138","volume":"17","author":"PR Walker","year":"2015","unstructured":"Walker PR, Migliorini D. The CD40\/CD40L axis in glioma progression and therapy. Neuro-Oncol. 2015;17:1428\u201330.","journal-title":"Neuro-Oncol"},{"key":"7321_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.20892\/j.issn.2095-3941.2019.0353","volume":"17","author":"C Zha","year":"2020","unstructured":"Zha C, Meng X, Li L, Mi S, Qian D, Li Z, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1\/RAGE\/IL-8 axis. Cancer Biol Med. 2020;17:154\u201368.","journal-title":"Cancer Biol Med"},{"key":"7321_CR51","doi-asserted-by":"publisher","first-page":"120784","DOI":"10.1016\/j.biomaterials.2021.120784","volume":"273","author":"J Wang","year":"2021","unstructured":"Wang J, Tang W, Yang M, Yin Y, Li H, Hu F, et al. Inflammatory tumor microenvironment responsive neutrophil exosomes-based drug delivery system for targeted glioma therapy. Biomaterials. 2021;273:120784.","journal-title":"Biomaterials"},{"key":"7321_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","volume":"15","author":"K Kramer","year":"2022","unstructured":"Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, et al. Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. J Hematol Oncol J Hematol Oncol. 2022;15:165.","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"7321_CR53","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","volume":"121","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013;121:745\u201351.","journal-title":"Blood"},{"key":"7321_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","volume":"20","author":"JN Sarkaria","year":"2018","unstructured":"Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncol. 2018;20:184\u201391.","journal-title":"Neuro-Oncol"},{"key":"7321_CR55","unstructured":"Xie Y, Yang F, He L, Huang H, Chao M, Cao H, et al. Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier. Neuron 2024;S0896-6273(24)00571-3."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07321-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07321-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:02:41Z","timestamp":1764871361000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07321-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7321"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07321-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All experiments were done by the guidelines of the Institutional Animal Care and Use Committee of Sichuan University (Chengdu, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1377"}}